Open AccessFLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations
Author(s) -
Fathi Amir T.,
Chabner Bruce A.
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0084
Subject(s) - medicine , midostaurin , sunitinib , myeloid leukemia , clinical trial , fms like tyrosine kinase 3 , oncology , tyrosine kinase , pharmacology , cancer research , mutation , cancer , biology , gene , receptor , biochemistry
Learning Objectives After completing this course, the reader will be able to: Incorporate FLT3 mutational status into the initial diagnostic evaluation of AML to acquire prognostic information and guide the aggressiveness of consolidative therapy. Select FLT3‐mutant patients to participate in clinical trials of FLT3 inhibitors in order to help provide important insight into the future utility and promise of these compounds as adjuncts to therapy.This article is available for continuing medical education credit at CME.TheOncologist.com Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis. Approximately one quarter of the patients with AML also carry an internal tandem duplication (ITD) mutation in the gene encoding FMS‐like tyrosine kinase 3 ( FLT3 ), which has a significantly deleterious impact on prognosis. The ITD mutation renders FLT3 constitutively active and leads to uncontrolled proliferation of the leukemic blast. Over the course of the last decade, a variety of compounds have been developed in preclinical and clinical studies as potent inhibitors of FLT3. Many of the earlier agents under investigation, such as lestaurtinib, midostaurin, and sunitinib, were initially developed as inhibitors of other tyrosine kinases and as targeted therapies in a variety of malignancies. These compounds have been demonstrated to have some efficacy in clinical trials of AML, mainly manifesting as transient decreases in circulating blasts correlating with effective in vivo suppression of the FLT3 target. Nevertheless, the cumbersome pharmacokinetics of some compounds and the suboptimal specificity and potency of others have limited their therapeutic efficacy. In the last few years, newer, more potent and specific agents have been under investigation, with the leading example being AC220. This agent has shown significant promise in early phases of clinical investigation, and is currently in more advanced clinical trials. Hope remains that FLT3 inhibition will be become an effective therapeutic adjunct to our current treatment approach to AML.